Medicare and Medicaid spending on GLP-1 drugs

How much do Medicare and Medicaid spend on GLP-1 drugs?

Medicare Part D spent $27.90 billion on GLP-1 drugs in 2024, CMS’s latest year, across 13 brand rows (2 of them insulin combination products), before manufacturer rebates; Ozempic alone was $12.97 billion. Medicaid pharmacy reimbursements for GLP-1 drugs were at least $12.05 billion in 2025 across at least 11,261,770 prescriptions, before the rebates manufacturers pay states.

These are aggregate program figures that CMS publishes: national totals by brand for Medicare Part D, and totals by state and quarter for Medicaid. No prescriber, pharmacy or patient is named. Figures are before rebates; see the CMS wording under each table.

Medicare Part D, by brand and year

Gross spending CMS reports for each GLP-1 brand in Part D, 2020 to 2024. “No data” means the CMS file has no figure for that brand in that year (for example, before the drug was sold).

OzempicSemaglutide$1,455,812,267$2,621,694,348$4,628,160,643$9,194,048,435$12,970,296,347
RybelsusSemaglutide$73,444,409$454,563,823$974,894,470$1,665,906,943$1,890,082,026
WegovySemaglutideNo dataNo dataNo data$199,774$301,283,291
MounjaroTirzepatideNo dataNo data$144,035,152$2,361,384,157$6,336,942,641
ZepboundTirzepatideNo dataNo dataNo dataNo data$387,343
Victoza 3-PakLiraglutide$1,545,815,415$1,422,292,583$1,238,594,872$1,004,635,145$203,063,050
Victoza 2-PakLiraglutide$349,476,159$334,897,957$319,205,509$317,213,565$77,832,721
LiraglutideLiraglutideNo dataNo dataNo dataNo data$48,095,824
TrulicityDulaglutide$3,284,873,062$4,702,174,724$6,225,291,668$7,363,856,224$5,454,134,725
Bydureon BciseExenatide Microspheres$266,160,951$379,243,467$355,078,758$284,056,759$215,354,678
ByettaExenatide$47,676,632$37,988,662$27,500,961$20,645,626$15,877,480
Soliqua 100-33Insulin Glargine/Lixisenatide$121,393,843$165,620,858$215,943,202$302,998,642$300,185,496
Xultophy 100-3.6Insulin Degludec/Liraglutide$71,921,892$75,755,898$77,994,459$91,415,961$91,255,682

Totals by ingredient

Ingredient20202021202220232024
Semaglutide (Ozempic, Rybelsus, Wegovy)$1.53 billion$3.08 billion$5.60 billion$10.86 billion$15.16 billion
Tirzepatide (Mounjaro, Zepbound)No dataNo data$144.0 million$2.36 billion$6.34 billion
Liraglutide (Victoza 3-Pak, Victoza 2-Pak, Liraglutide)$1.90 billion$1.76 billion$1.56 billion$1.32 billion$329.0 million
Dulaglutide (Trulicity)$3.28 billion$4.70 billion$6.23 billion$7.36 billion$5.45 billion
Exenatide (Bydureon Bcise, Byetta)$313.8 million$417.2 million$382.6 million$304.7 million$231.2 million
Insulin glargine and lixisenatide (Soliqua 100-33)$121.4 million$165.6 million$215.9 million$303.0 million$300.2 million
Insulin degludec and liraglutide (Xultophy 100-3.6)$71.9 million$75.8 million$78.0 million$91.4 million$91.3 million
All GLP-1 rows$7.22 billion$10.19 billion$14.21 billion$22.61 billion$27.90 billion

Beneficiary counts are per brand and are not added up, because one person can fill prescriptions for more than one brand in a year.

Claims, beneficiaries and averages, 2024

Ozempic$12,970,296,34710,417,1821,952,637$1,245$6,642
Rybelsus$1,890,082,0261,251,733309,993$1,510$6,097
Wegovy$301,283,291211,57552,961$1,424$5,689
Mounjaro$6,336,942,6415,105,397894,581$1,241$7,084
Zepbound$387,343353245$1,097$1,581
Victoza 3-Pak$203,063,050181,06862,754$1,121$3,236
Victoza 2-Pak$77,832,721108,52141,126$717$1,893
Liraglutide$48,095,82462,25424,405$773$1,971
Trulicity$5,454,134,7254,305,141788,716$1,267$6,915
Bydureon Bcise$215,354,678178,93138,059$1,204$5,658
Byetta$15,877,48011,7123,043$1,356$5,218
Soliqua 100-33$300,185,496273,40759,472$1,098$5,048
Xultophy 100-3.6$91,255,68257,19713,672$1,595$6,675

CMS describes the Part D figures this way, in its catalog entry for the dataset:

“Drug spending metrics for Part D drugs are based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments.”

“The Part D spending metrics do not reflect any manufacturers’ rebates or other price concessions as CMS is prohibited from publicly disclosing such information.”

Medicare Part B

A search of CMS’s Medicare Part B Spending by Drug file (2020 to 2024, read Nov 15, 2026) for generic names containing “glutide”, “xenatide”, “tirzepatide”, “lixisenatide” returned no rows. CMS describes that file as covering “drugs administered in doctors’ offices and other outpatient settings,” and its Part D file as covering “drugs patients generally administer themselves.” This is a statement about that file only.

“Drug spending metrics for Part B drugs represent the full value of the product, including the Medicare payment and beneficiary liability.”

Medicaid, national

Pharmacies were reimbursed at least $12.05 billion for GLP-1 drugs paid through Medicaid nationwide in 2025, across at least 11,261,770 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 81 rows of 513, so these figures are floors.

2020at least $283,898,491No data$567,508,684at least $596,408,518at least $193,861,115at least $671,511$7,761,540$5,421,897at least $1,655,531,756
2021at least $554,820,690No data$680,639,494at least $1,188,068,204at least $134,241,933at least $1,080,158$9,594,531$4,796,567at least $2,573,241,576
2022at least $1,149,248,802at least $34,060,250$722,777,322$2,153,391,817at least $98,166,895at least $359,908$12,192,603$4,138,825at least $4,174,336,421
2023at least $2,911,348,586at least $439,944,750$722,050,605$2,839,397,030at least $82,702,773at least $11,027$9,422,199$3,295,077at least $7,008,172,046
2024at least $5,107,538,873at least $1,205,743,835$294,458,438$2,163,300,920at least $66,016,586No data$6,859,607$2,280,203at least $8,846,198,462
2025at least $6,613,338,249at least $3,323,545,465$145,922,324$1,948,292,919at least $15,363,655No data$4,455,588$1,460,353at least $12,052,378,553
2026 (Q1)at least $1,251,443,577at least $911,460,172at least $24,183,285$391,170,412at least $137,347No data$762,625$275,378at least $2,579,432,797

National figures are the rows CMS publishes under the state code XX. The latest year shows only the quarters CMS has posted.

By product, 2025

Bydureonat least $12,367,705at least 15,1013 of 9
Byettaat least $2,689,012at least 3,2114 of 16
Liraglutide (generic name listing)$79,063,400182,4280 of 52
Mounjaroat least $1,515,725,769at least 1,416,80721 of 96
Ozempicat least $3,754,483,078at least 3,695,7106 of 53
Rybelsusat least $258,033,553at least 201,29911 of 35
Saxenda$34,485,96629,0570 of 8
Soliqua$4,455,5885,1680 of 8
Trulicity$1,948,292,9191,940,7950 of 64
Victoza$32,372,95851,2260 of 16
Wegovyat least $2,600,821,618at least 1,995,7184 of 44
Xultophy$1,460,3531,1420 of 8
Zepboundat least $1,807,819,696at least 1,723,70232 of 98
Exenatide (generic name listing)$306,9384060 of 6

Medicaid, by state

Each state’s GLP-1 rows for 2025, all quarters. Each state name links to that state’s page, with every year from 2020 and each quarter.

Alabamaat least $72,334,685at least 71,83157 of 171
Alaskaat least $22,152,586at least 23,249102 of 202
Arizonaat least $98,252,621at least 93,64576 of 215
Arkansasat least $18,871,001at least 24,039111 of 279
Californiaat least $3,462,543,976at least 3,090,45250 of 319
Coloradoat least $127,199,098at least 123,01269 of 284
Connecticutat least $202,814,053at least 174,55321 of 141
Delawareat least $21,354,918at least 55,674104 of 218
District of Columbiaat least $28,122,591at least 27,754115 of 265
Floridaat least $128,079,710at least 133,48285 of 252
Georgiaat least $52,526,193at least 59,45676 of 283
Hawaiiat least $33,872,236at least 30,47849 of 144
Idahoat least $46,072,822at least 45,95442 of 156
Illinoisat least $305,552,662at least 288,52265 of 287
Indianaat least $204,764,005at least 190,16282 of 297
Iowaat least $87,363,112at least 88,51883 of 227
Kansasat least $53,573,102at least 50,90336 of 161
Kentuckyat least $238,314,570at least 274,53897 of 292
Louisianaat least $230,946,267at least 230,35963 of 229
Maineat least $40,616,132at least 41,65541 of 162
Marylandat least $142,812,988at least 148,648119 of 308
Massachusettsat least $404,519,821at least 399,03098 of 345
Michiganat least $681,063,451at least 608,028102 of 366
Minnesotaat least $255,696,545at least 230,59479 of 337
Mississippiat least $70,718,721at least 61,646115 of 285
Missouriat least $284,863,196at least 285,10547 of 165
Montanaat least $22,195,107at least 22,71947 of 139
Nebraskaat least $36,117,422at least 37,33548 of 144
Nevadaat least $81,868,395at least 70,93984 of 279
New Hampshireat least $37,487,064at least 34,65267 of 190
New Jerseyat least $151,445,199at least 165,667135 of 289
New Mexicoat least $64,499,377at least 64,832113 of 255
New Yorkat least $941,187,086at least 816,61667 of 245
North Carolinaat least $589,996,654at least 484,71294 of 338
North Dakotaat least $3,605,150at least 5,85257 of 100
Ohioat least $406,954,834at least 425,347115 of 357
Oklahomaat least $83,573,455at least 82,36566 of 264
Oregonat least $67,351,293at least 72,793106 of 290
Pennsylvaniaat least $951,405,819at least 844,001107 of 366
Puerto Ricoat least $51,822,634at least 48,73237 of 148
Rhode Islandat least $48,888,755at least 46,69181 of 250
South Carolinaat least $64,945,523at least 65,093105 of 279
South Dakotaat least $15,709,847at least 15,60240 of 113
Tennesseeat least $144,104,065at least 136,02345 of 189
Texasat least $179,016,062at least 172,353114 of 244
Utahat least $28,648,950at least 28,00797 of 247
Vermontat least $18,537,316at least 17,16338 of 133
Virginiaat least $230,109,559at least 227,621123 of 329
Washingtonat least $82,653,211at least 111,20298 of 281
West Virginiaat least $91,584,548at least 94,99953 of 149
Wisconsinat least $327,847,844at least 302,67218 of 168
Wyomingat least $2,244,963at least 2,31576 of 140

A state marked “at least” or “Suppressed” has rows CMS withheld, so its full amount is unknown and it cannot be ranked against other states; its place in this order reflects only the rows CMS published.

2026, quarters posted so far (Q1)

Alabamaat least $22,601,198at least 21,92614 of 47
Alaskaat least $5,305,125at least 5,38514 of 39
Arizonaat least $17,261,573at least 15,75118 of 55
Arkansasat least $7,485,924at least 8,39428 of 74
Californiaat least $537,681,425at least 498,61916 of 86
Coloradoat least $40,344,875at least 38,30225 of 81
Connecticutat least $45,117,089at least 35,5919 of 40
Delawareat least $5,035,559at least 10,85531 of 58
District of Columbiaat least $7,163,586at least 7,41041 of 83
Floridaat least $29,953,764at least 29,76921 of 65
Georgiaat least $14,835,416at least 16,34525 of 83
Hawaiiat least $7,389,266at least 6,1099 of 35
Idahoat least $12,391,377at least 12,33911 of 40
Illinoisat least $55,278,302at least 52,09311 of 71
Indianaat least $46,413,529at least 41,44419 of 82
Iowaat least $20,245,786at least 19,75032 of 67
Kansasat least $9,495,187at least 8,63815 of 42
Kentuckyat least $48,092,559at least 57,53430 of 79
Louisianaat least $44,615,662at least 42,74227 of 71
Maineat least $11,179,202at least 11,11811 of 40
Marylandat least $39,661,203at least 39,61739 of 94
Massachusettsat least $121,171,872at least 116,36723 of 83
Michiganat least $155,810,081at least 139,55733 of 99
Minnesotaat least $56,052,562at least 50,35218 of 85
Mississippiat least $20,785,939at least 17,80428 of 76
Missouriat least $121,205,304at least 116,88410 of 38
Montanaat least $5,733,788at least 5,67411 of 33
Nebraskaat least $9,426,206at least 9,27814 of 41
Nevadaat least $24,907,445at least 19,39627 of 88
New Hampshireat least $3,857,847at least 3,91318 of 45
New Jerseyat least $27,399,401at least 28,33336 of 74
New Mexicoat least $16,567,965at least 16,65931 of 73
New Yorkat least $255,741,996at least 217,80216 of 58
North Carolinaat least $145,713,648at least 119,14330 of 99
North Dakotaat least $2,191,959at least 2,33515 of 26
Ohioat least $88,482,152at least 90,65426 of 96
Oklahomaat least $19,672,034at least 19,43525 of 75
Oregonat least $16,562,209at least 17,83832 of 81
Pennsylvaniaat least $69,383,793at least 68,53427 of 85
Puerto Ricoat least $11,234,524at least 10,7868 of 25
Rhode Islandat least $13,328,198at least 12,34023 of 69
South Carolinaat least $15,775,344at least 16,01831 of 71
South Dakotaat least $4,116,128at least 3,93617 of 34
Tennesseeat least $70,662,190at least 62,73414 of 54
Texasat least $54,896,332at least 50,83530 of 72
Utahat least $7,788,657at least 7,68934 of 79
Vermontat least $5,807,912at least 5,2376 of 33
Virginiaat least $52,912,733at least 51,40933 of 87
Washingtonat least $24,933,072at least 30,84122 of 72
West Virginiaat least $25,021,572at least 25,52010 of 41
Wisconsinat least $99,701,709at least 91,3054 of 45
Wyomingat least $1,621,808at least 1,5569 of 38

A state marked “at least” or “Suppressed” has rows CMS withheld, so its full amount is unknown and it cannot be ranked against other states; its place in this order reflects only the rows CMS published.

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Questions answered from this data

How the rows are chosen

Part D rows are kept when CMS’s generic name is exactly one of: Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, Exenatide, Lixisenatide, Insulin glargine and lixisenatide, Insulin degludec and liraglutide (with “Exenatide Microspheres” counted as exenatide), using CMS’s “Overall” row for each brand. Medicaid rows are kept when the first word of the product name CMS gives (the first 10 characters of the FDA listing name) is one of the brand or generic names listed on the methodology page. Retatrutide and cagrilintide were also searched for in both files; neither name appears in either.

Common questions

Do these figures include manufacturer rebates?

No. CMS says the Part D figures do not reflect manufacturer rebates or other price concessions, and its Medicaid total amount reimbursed is not reduced by the rebates manufacturers pay states.

Why do some Medicaid figures say “at least” or “Suppressed”?

CMS suppresses some state rows and leaves their counts and amounts blank. A total that includes suppressed rows is shown as at least the published sum; a total where every row is suppressed is shown as suppressed, never as zero.

Does Medicare Part D cover Wegovy and Zepbound?

This page reports only what CMS’s spending files show. Wegovy and Zepbound appear in the Part D file with the spending and beneficiary counts shown in the table above; the file does not say what each claim was for.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.